ArticleFrontiers in oncology2019

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.

Elena Tirrò et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.